HPR and neoplasm: In order to increase tumor targeting, SL-HPR were then decorated with the anti-GD2 antibody (a-GD2 moAb), specifically recognizing the disialoganglioside GD2 highly expressed on the cell surface of melanoma and NB cells, and whose expression on healthy tissues is very limited and restricted to cerebellum and peripheral nerves [85,86].